Nano drops a million times smaller than a teardrop explodes 19th century theory

Droplets emanating from a molecular "nano-tap" would behave very differently from those from a household tap 1 million times larger - researchers at the University of Warwick have found. This is potentially crucial step for a number of emerging nano technologies, e.g., manufacture of nano-sized drug particles, lab-on-chip devices for in situ diagnostics, and 3D printers capable of nanoscale resolution.

Molecular simulations of liquid jets, akin to a stream of water pouring out of a nano-tap, have been used by researchers at the University of Warwick to probe the nanoscale production of droplets. The reduction in scale from the household jet is equivalent to that of Big Ben being shrunk to the size of a human hair.

The breakup of jets has a classical theory, devised by Rayleigh and Plateau in the 19th century, but this was found to be inadequate at the nanoscale, where one cannot ignore the inherent jostling of molecules that produces nano-waves on the liquid's boundary. The new theory developed captures these nano-waves and can accurately predict the production of nanodroplets.

This theory predicts that droplets are easier to produce at the nanoscale than from the household tap, with nano-waves acting to breakup jets that would be classically stable.

Prof. Duncan Lockerby from the School of Engineering at the University of Warwick comments: "Our research is concerned with developing new understanding for emerging nanoscale technologies, using simulation for design techniques, and this research exemplifies this effort with potential applications in manufacturing and healthcare."

Dr James Sprittles from the Mathematics Institute at the University of Warwick comments: "It has been wonderful to work on a problem whose classical solution I teach to 3rd year undergraduates and to develop a new updated theory for application at the nanoscale"

Zhao C, Sprittles J, Lockerby D.
Revisiting the Rayleigh-Plateau instability for the nanoscale.
Journal of Fluid Mechanics, 861, R3. doi: 10.1017/jfm.2018.950.

Most Popular Now

Novartis receives FDA approval for Mayzent® (sipon…

Novartis today announced that the US Food and Drug Administration (FDA) has approved Mayzent® (siponimod) for the treatment of adults with relapsing forms of multiple scl...

Compound that kills drug-resistant fungi is isolat…

Antimicrobial and antifungal resistance, which describe the ability of bacteria and other pathogens to resist the effects of drugs to which they were once sensitive, is a...

First bacterial genome created entirely with a com…

All the genome sequences of organisms known throughout the world are stored in a database belonging to the National Center for Biotechnology Information in the United Sta...

Liver, colon cancer cells thwarted by compounds de…

The plant that adds flavor, color and bitterness to beer also produces a primary compound that thwarts cancer cells, and two important derivatives of the compound do as w...

Clinical trial finds therapy to be well-tolerated …

A phase I clinical trial that set out to assess the safety of a new combination therapy for a type of aggressive brain tumour has found the treatment to be well tolerated...

Immune cells fighting blood cancer visualized for …

When cancer escapes the immune system, our defenses are rendered powerless and are unable to fight against the disease. Chimeric antigen receptor T cells (CAR T cells) re...

Boehringer Ingelheim announces FDA and EMA regulat…

Boehringer Ingelheim has filed for regulatory approval of nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD) with the FDA and E...

FDA approves treatment for patients with a type of…

The U.S. Food and Drug Administration today approved Cimzia (certolizumab pegol) injection for treatment of adults with a certain type of inflammatory arthritis called no...

Selumetinib granted US Breakthrough Therapy Design…

AstraZeneca and MSD, Inc., Kenilworth, NJ, US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that the US Food and Drug Administration (FDA) ha...

Novartis adds clinical and preclinical anti-inflam…

Novartis announced that it is adding to its broad portfolio of immunomodulatory medicines with the planned acquisition of IFM Tre, a subsidiary of IFM Therapeutics LLC fo...

Forxiga approved in Japan for type-1 diabetes

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Forxiga (dapagliflozin) as an oral adjunct treatment to insulin for adults with type-1 diabetes (T...

Novartis continues transformation into a leading m…

Novartis today completed the spin-off of the Alcon eye care devices business through a dividend-in-kind distribution to holders of Novartis shares and ADRs (American Depo...